Covax to purchase 40M doses of Pfizer, BioNTech COVID-19 vaccine
The Covax global vaccine initiative has reached a deal with Pfizer and BioNTech for 40 million doses of the Pfizer-BioNTech COVID-19 vaccine. Read More
Precision BioSciences nabs patent for CAR construct tech
Precision BioSciences has received a notice of allowance from the U.S. Patent and Trademark Office for patent application, No. 16/908, 030. The patent application covers PBCAR19B, a next-generation, stealth cell, CD19 allogeneic chimeric antigen receptor (CAR) T candidate for patients with relapsed/refractory non-Hodgkin lymphoma. Read More
Canada ups COVID-19 vaccine order from Novavax to 76M doses
Novavax has finalized an agreement with the Canadian government to supply up to 76 million doses of NVX-CoV2373, a recombinant protein-based COVID-19 vaccine. Read More
Medigen Vaccine, Dynavax begin phase II trial for subunit COVID-19 vaccine
Medigen Vaccine Biologics and Dynavax Technologies have dosed the first participant in a phase II clinical trial evaluating Medigen's COVID-19 vaccine candidate, MVC-COV1901, a subunit vaccine with a recombinant spike-2P antigen adjuvanted with Dynavax's CpG 1018. Read More
Evozyne to develop synthetic proteins for Takeda gene therapies
Molecular engineering company Evozyne has signed a strategic collaboration and license agreement with Takeda Pharmaceutical. The partnership's aim is to develop proteins that can be incorporated into next-generation gene therapies for genetic disorders within inborn errors of metabolism and lysosomal storage diseases. Read More
Shark-derived proteins may be effective against COVID-19
Elasmogen, in collaboration with the University of Minnesota, has identified a next-generation protein-based drug with the potential to stop COVID-19 infections. Read More
Vaxess receives $2M from the U.S. government
Vaxess Technologies has been awarded a grant from the National Science Foundation and a subcontract from the Defense Advanced Research Projects Agency, a branch of the U.S. Department of Defense, totaling $2 million if all milestones are achieved. Read More
Sartorius contributes to Penn State cell culture facility
Sartorius Stedim Biotech has donated $1.5 million to Pennsylvania State University (Penn State) for the creation of the Sartorius Cell Culture Facility, which is slated to open later this year on the University Park campus. Read More
Lilly's mAb highly protective against COVID-19 in nursing homes
Eli Lilly's monoclonal antibody (mAb) LY-CoV555 (bamlanivimab) significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities, the firm said. Read More
Humanigen expands partnership with BARDA for COVID-19 mAb manufacturing
Humanigen has expanded its cooperative research and development agreement with the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority (BARDA). The agreement supports the development of the monoclonal antibody lenzilumab in advance of a potential emergency use authorization for COVID-19. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
